Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05775939
Other study ID # 22D.705
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 20, 2023
Est. completion date January 1, 2026

Study information

Verified date March 2024
Source Thomas Jefferson University
Contact Yevgeniy Vinogradskiy, MD
Phone 215-955-3605
Email yevgeniy.vinogradskiy@jefferson.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial examines positron emission tomography (PET)/computed tomography (CT) in evaluating cardiac radiation damage in patients with lung or esophageal cancer. As part of the treatment for lung or esophageal cancer, patients will undergo radiation therapy. Sometimes, during this treatment, the heart is also subjected to some radiation which could affect its function, either increasing or decreasing the function. It is not known the consequences of this change nor is it known if doctors can detect the changes associated with the radiation. Sarcoidosis FDG positron emission tomography (PET)-computed tomography (CT) scans are a common way to image cardiac inflammation and myocardial viability. This study may help doctors image the heart before, during and after radiotherapy to monitor any changes.


Description:

PRIMARY OBJECTIVE: I. To characterize radiation-related functional imaging changes in the heart using sarcoidosis fludeoxyglucose F-18 (FDG) PET-CT imaging. SECONDARY OBJECTIVES: I. 1. To evaluate the ability of imaging changes in the heart to predict for overall survival (OS). II. To evaluate the ability of imaging changes in the heart to predict for cardiac toxicity. III. To evaluate the ability of imaging changes in the heart to predict for cardiac related death. EXPLORATORY OBJECTIVES: I. To evaluate radiation treatment planning strategies to reduce risk of cardiotoxicity. II. To determine the correlation between sarcoidosis FDG PET-CT scans and oncologic FDG PET-CT scans. OUTLINE: Patients undergo sarcoidosis FDG PET-CT of the heart before, during and, after radiotherapy. After completion of study treatment, patients are followed up at 12 and 24 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date January 1, 2026
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Provide signed and dated informed consent form - Willing to comply with all study procedures and be available for the duration of the study - Male or female, aged >= 18 - Life expectancy >= 3 months as assessed by Radiation Oncologist - Mean heart dose estimated by Radiation Oncologist to be >= 5 Gy (physics dose or biologically equivalent dose) - Pathologically proven (either histologic or cytologic) proven lung cancer or esophageal cancer - Planned radiation treatment course for management of lung or esophageal cancer * Both standard and hypofractionation schedules are permitted Exclusion Criteria: - Contraindication for FDG PET-CT scans as assessed by the radiation oncologist or nuclear medicine radiologist - Palliative radiation doses defined as 20 Gy in 5 fractions

Study Design


Intervention

Other:
Fludeoxyglucose F-18
Given FDG
Procedure:
Positron Emission Tomography
Undergo PET-CT
Computed Tomography
Undergo PET-CT
Other:
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in mean standardized uptake value (SUV) changes in the heart Measured by sarcoidosis fludeoxyglucose F-18 (FDG) positron emission tomography (PET)-computed tomography (CT) scans. Up to 30 months after radiotherapy
Secondary Ability of pre- to post-radiotherapy SUV changes in the heart Measured by sarcoidosis FDG PET-CT scans. Up to 30 months after radiotherapy
Secondary Overall survival Survival Up to 30 months after radiotherapy
Secondary Cardiac toxicity Assessed using >= grade 2 and >= grade cardiac events using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Up to 30 months after radiotherapy
Secondary Cardiac toxicity judged to be secondary to radiotherapy by cardiologist and radiation oncologist Judged to be secondary to radiotherapy by cardiologist and radiation oncologist Up to 30 months after radiotherapy
Secondary Cardiac related death Death Up to 30 months after radiotherapy
See also
  Status Clinical Trial Phase
Recruiting NCT04931017 - Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer Phase 2
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Not yet recruiting NCT06038526 - Evaluation of Canakinumab in High-Risk Former-Smokers Phase 2
Terminated NCT02856581 - Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes Phase 3
Completed NCT04922697 - Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study N/A
Recruiting NCT04644952 - The Rise in Robotic Atypical Segmentectomies
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05407168 - Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool N/A
Completed NCT04267874 - Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study Early Phase 1
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Recruiting NCT03709953 - Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma Phase 2
Active, not recruiting NCT03267524 - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Completed NCT02237183 - Iloprost in Preventing Lung Cancer in Former Smokers Phase 1
Recruiting NCT04783168 - Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study N/A
Completed NCT04635761 - Awareness, Information, and Resources for Lung Cancer Screening Program for Community-Partnered Lung Cancer Screening N/A
Recruiting NCT06445192 - Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial N/A
Active, not recruiting NCT03164486 - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide Early Phase 1
Recruiting NCT05802186 - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study N/A
Active, not recruiting NCT01696968 - Screening for Lung Cancer in Older Patients (PLCO Screening Trial) N/A